M&A, People

Tesaro execs split $304M windfall from $5.1B GlaxoSmithKline buyout

Tesaro CEO Lonnie Moulder may not have landed the deal he originally wanted for selling the biotech, but he’s not exactly coming away empty-handed.

Lonnie Moulder

As part of their detailed look back at the deal, the biotech also revealed that Moulder will receive a total of $155,854,551 for his stock, options and RSU grant. President Mary Lynne Hedley gets $112,500,429.

Mary Lynne Hedley

That’s all substantially better than the rest of the executive crew, each of whom gets millions. Here’s the full roster from the SEC filing.

  • Timothy Pearson, CFO: $11.8 million
  • Grant Bogle, chief commercial officer: $5.3 million
  • Joseph Farmer, general counsel: $6.1 million
  • Martin Huber, chief medical officer: $7 million
  • Orlando Oliveira, general manager, international: $6 million

The top investor on Tesaro’s board was NEA, represented by David Mott, which gets $783 million in the buyout. Kleiner Perkins, which was represented by Beth Seidenberg, bags $167 million.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->